Tafluprost has been shown to lower elevated intraocular pressure (IOP) in patients with open-angle glaucoma and hypermetropia. Tafluprost, a prostate analog, is a selective FP prostaglandin receptor agonist that acts primarily on the uveoscleral pathway of aqueous drainage to increase aqueous outflow from the uveoscleral pathway, thereby lowering IOP. Adverse effects: Long-term use of this drug may cause skin pigmentation around the eyes, thickening and lengthening of eyelashes, and darkening of iris color. Precautions: It is not recommended for use with caution in patients with uveitis and patients with iritis, as it has the potential to exacerbate the progression of inflammation. In addition has the effect of increasing macular edema, should follow the doctor’s instructions to regulate the application. Appearance of discomfort, please timely hospital consultation, under the guidance of the physician to use the drug, avoid self-medication blindly.